Unresectable Paraganglioma
5 clinical trials · Condition
◉ Watch Unresectable Paraganglioma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (NCT04394858) | National Cancer Institute (NCI) | 2021-03-17 |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers (NCT04106843) | M.D. Anderson Cancer Center | 2019-06-13 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (NCT02721732) | M.D. Anderson Cancer Center | 2016-08-15 |
| Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery (NCT02302833) | M.D. Anderson Cancer Center | 2015-02-17 |
| Dovitinib in Neuroendocrine Tumors (NCT01635907) | Abramson Cancer Center at Penn Medicine | 2012-06-01 |
Track Unresectable Paraganglioma automatically
Every clearance here is in the API, with alerts when new ones post.